Neurodegenerative Diseases Drugs Market Size, Share, Trends, Growth, and Forecasts for 2025 - 2032

Table of Content

1. Executive Summary
   1. Global Neurodegenerative Diseases Drugs Market Snapshot, 2025 and 2032
   2. Market Opportunity Assessment, 2025 - 2032, US$ Bn
   3. Key Market Trends
   4. Future Market Projections
   5. Premium Market Insights
   6. Industry Developments and Key Market Events
   7. PMR Analysis and Recommendations
2. Market Overview
   1. Market Scope and Definition
   2. Market Dynamics
      1. Drivers
      2. Restraints
      3. Opportunity
      4. Challenges
      5. Key Trends
   3. Macro-economic Factors
      1. Increasing Prevalence of Neurodegenerative Diseases
      2. Government Initiatives to Improve Research Activities
   4. COVID-19 Impact Analysis
   5. Forecast Factors - Relevance and Impact
3. Value Added Insights
   1. Regulatory Landscape
   2. Drug Class Adoption Analysis
   3. Key Deals and Mergers
   4. PESTLE Analysis
   5. Porter’s Five Force Analysis
4. Global Neurodegenerative Diseases Drugs Market Outlook
   1. Key Highlights
      1. Market Size (US$ Bn) and Y-o-Y Growth
      2. Absolute $ Opportunity
   2. Market Size (US$ Bn) Analysis and Forecast
      1. Historical Market Size (US$ Bn) Analysis, 2019-2024
      2.  Market Size (US$ Bn) Analysis and Forecast, 2025-2032
   3. Global Neurodegenerative Diseases Drugs Market Outlook: Drug Class
      1. Introduction / Key Findings
      2. Historical Market Size (US$ Bn) Analysis, By Drug Class, 2019 - 2024
      3.  Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2025 - 2032
         1. Immunomodulator
         2. Interferons
         3. Decarboxylase Inhibitors
         4. Dopamine Agonists
         5. Others
      4. Market Attractiveness Analysis: Drug Class
   4. Global Neurodegenerative Diseases Drugs Market Outlook: Disease Indication
      1. Introduction / Key Findings
      2. Historical Market Size (US$ Bn) Analysis, By Disease Indication, 2019 - 2024
      3.  Market Size (US$ Bn) Analysis and Forecast, By Disease Indication, 2025 - 2032
         1. Multiple Sclerosis
         2. Parkinson’s Disease
         3. Alzheimer's Disease
         4. Spinal Muscular Atrophy (SMA)
         5. Others
      4. Market Attractiveness Analysis: Disease Indication
   5. Global Neurodegenerative Diseases Drugs Market Outlook: Route of Administration
      1. Introduction / Key Findings
      2. Historical Market Size (US$ Bn) Analysis, By Route of Administration, 2019 - 2024
      3.  Market Size (US$ Bn) Analysis and Forecast, By Route of Administration, 2025 - 2032
         1. Oral
         2. Injection
         3. Transdermal
      4. Market Attractiveness Analysis: Route of Administration
   6. Global Neurodegenerative Diseases Drugs Market Outlook: End Use
      1. Introduction / Key Findings
      2. Historical Market Size (US$ Bn) Analysis, By End Use, 2019 - 2024
      3.  Market Size (US$ Bn) Analysis and Forecast, By End Use, 2025 - 2032
         1. Hospital Pharmacy
         2. Retail Pharmacy
         3. Online Pharmacy
      4. Market Attractiveness Analysis: End Use
5. Global Neurodegenerative Diseases Drugs Market Outlook: Region
   1. Key Highlights
   2. Historical Market Size (US$ Bn) Analysis, By Region, 2019 - 2024
   3.  Market Size (US$ Bn) Analysis and Forecast, By Region, 2025 - 2032
      1. North America
      2. Europe
      3. East Asia
      4. South Asia and Oceania
      5. Latin America
      6. Middle East & Africa
   4. Market Attractiveness Analysis: Region
6. North America Neurodegenerative Diseases Drugs Market Outlook
   1. Key Highlights
   2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2024
      1. By Country
      2. By Drug Class
      3. By Disease Indication
      4. By Route of Administration
      5. By End Use
   3.  Market Size (US$ Bn) Analysis and Forecast, By Country, 2025 - 2032
      1. U.S.
      2. Canada
   4.  Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2025 - 2032
      1. Immunomodulator
      2. Interferons
      3. Decarboxylase Inhibitors
      4. Dopamine Agonists
      5. Others
   5.  Market Size (US$ Bn) Analysis and Forecast, By Disease Indication, 2025 - 2032
      1. Multiple Sclerosis
      2. Parkinson’s Disease
      3. Alzheimer's Disease
      4. Spinal Muscular Atrophy (SMA)
      5. Others
   6.  Market Size (US$ Bn) Analysis and Forecast, By Route of Administration, 2025 - 2032
      1. Oral
      2. Injection
      3. Transdermal
   7.  Market Size (US$ Bn) Analysis and Forecast, By End Use, 2025 - 2032
      1. Hospital Pharmacy
      2. Retail Pharmacy
      3. Online Pharmacy
   8. Market Attractiveness Analysis
7. Europe Neurodegenerative Diseases Drugs Market Outlook
   1. Key Highlights
   2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2024
      1. By Country
      2. By Drug Class
      3. By Disease Indication
      4. By Route of Administration
      5. By End Use
   3.  Market Size (US$ Bn) Analysis and Forecast, By Country, 2025 - 2032
      1. Germany
      2. France
      3. U.K.
      4. Italy
      5. Spain
      6. Russia
      7. Türkiye
      8. Rest of Europe
   4.  Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2025 - 2032
      1. Immunomodulator
      2. Interferons
      3. Decarboxylase Inhibitors
      4. Dopamine Agonists
      5. Others
   5.  Market Size (US$ Bn) Analysis and Forecast, By Disease Indication, 2025 - 2032
      1. Multiple Sclerosis
      2. Parkinson’s Disease
      3. Alzheimer's Disease
      4. Spinal Muscular Atrophy (SMA)
      5. Others
   6.  Market Size (US$ Bn) Analysis and Forecast, By Route of Administration, 2025 - 2032
      1. Oral
      2. Injection
      3. Transdermal
   7.  Market Size (US$ Bn) Analysis and Forecast, By End Use, 2025 - 2032
      1. Hospital Pharmacy
      2. Retail Pharmacy
      3. Online Pharmacy
   8. Market Attractiveness Analysis
8. East Asia Neurodegenerative Diseases Drugs Market Outlook
   1. Key Highlights
   2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2024
      1. By Country
      2. By Drug Class
      3. By Disease Indication
      4. By Route of Administration
      5. By End Use
   3.  Market Size (US$ Bn) Analysis and Forecast, By Country, 2025 - 2032
      1. China
      2. Japan
      3. South Korea
   4.  Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2025 - 2032
      1. Immunomodulator
      2. Interferons
      3. Decarboxylase Inhibitors
      4. Dopamine Agonists
      5. Others
   5.  Market Size (US$ Bn) Analysis and Forecast, By Disease Indication, 2025 - 2032
      1. Multiple Sclerosis
      2. Parkinson’s Disease
      3. Alzheimer's Disease
      4. Spinal Muscular Atrophy (SMA)
      5. Others
   6.  Market Size (US$ Bn) Analysis and Forecast, By Route of Administration, 2025 - 2032
      1. Oral
      2. Injection
      3. Transdermal
   7.  Market Size (US$ Bn) Analysis and Forecast, By End Use, 2025 - 2032
      1. Hospital Pharmacy
      2. Retail Pharmacy
      3. Online Pharmacy
   8. Market Attractiveness Analysis
9. South Asia & Oceania Neurodegenerative Diseases Drugs Market Outlook
   1. Key Highlights
   2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2024
      1. By Country
      2. By Drug Class
      3. By Disease Indication
      4. By Route of Administration
      5. By End Use
   3.  Market Size (US$ Bn) Analysis and Forecast, By Country, 2025 - 2032
      1. India
      2. Southeast Asia
      3. ANZ
      4. Rest of South Asia & Oceania
   4.  Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2025 - 2032
      1. Immunomodulator
      2. Interferons
      3. Decarboxylase Inhibitors
      4. Dopamine Agonists
      5. Others
   5.  Market Size (US$ Bn) Analysis and Forecast, By Disease Indication, 2025 - 2032
      1. Multiple Sclerosis
      2. Parkinson’s Disease
      3. Alzheimer's Disease
      4. Spinal Muscular Atrophy (SMA)
      5. Others
   6.  Market Size (US$ Bn) Analysis and Forecast, By Route of Administration, 2025 - 2032
      1. Oral
      2. Injection
      3. Transdermal
   7.  Market Size (US$ Bn) Analysis and Forecast, By End Use, 2025 - 2032
      1. Hospital Pharmacy
      2. Retail Pharmacy
      3. Online Pharmacy
   8. Market Attractiveness Analysis
10. Latin America Neurodegenerative Diseases Drugs Market Outlook
    1. Key Highlights
    2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2024
       1. By Country
       2. By Drug Class
       3. By Disease Indication
       4. By Route of Administration
       5. By End Use
    3.  Market Size (US$ Bn) Analysis and Forecast, By Country, 2025 - 2032
       1. Brazil
       2. Mexico
       3. Rest of Latin America
    4.  Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2025 - 2032
       1. Immunomodulator
       2. Interferons
       3. Decarboxylase Inhibitors
       4. Dopamine Agonists
       5. Others
    5.  Market Size (US$ Bn) Analysis and Forecast, By Disease Indication, 2025 - 2032
       1. Multiple Sclerosis
       2. Parkinson’s Disease
       3. Alzheimer's Disease
       4. Spinal Muscular Atrophy (SMA)
       5. Others
    6.  Market Size (US$ Bn) Analysis and Forecast, By Route of Administration, 2025 - 2032
       1. Oral
       2. Injection
       3. Transdermal
    7.  Market Size (US$ Bn) Analysis and Forecast, By End Use, 2025 - 2032
       1. Hospital Pharmacy
       2. Retail Pharmacy
       3. Online Pharmacy
    8. Market Attractiveness Analysis
11. Middle East & Africa Neurodegenerative Diseases Drugs Market Outlook
    1. Key Highlights
    2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2024
       1. By Country
       2. By Drug Class
       3. By End Use
    3.  Market Size (US$ Bn) Analysis and Forecast, By Country, 2025 - 2032
       1. GCC Countries
       2. Egypt
       3. South Africa
       4. Northern Africa
       5. Rest of Middle East & Africa
    4.  Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2025 - 2032
       1. Immunomodulator
       2. Interferons
       3. Decarboxylase Inhibitors
       4. Dopamine Agonists
       5. Others
    5.  Market Size (US$ Bn) Analysis and Forecast, By Disease Indication, 2025 - 2032
       1. Multiple Sclerosis
       2. Parkinson’s Disease
       3. Alzheimer's Disease
       4. Spinal Muscular Atrophy (SMA)
       5. Others
    6.  Market Size (US$ Bn) Analysis and Forecast, By Route of Administration, 2025 - 2032
       1. Oral
       2. Injection
       3. Transdermal
    7.  Market Size (US$ Bn) Analysis and Forecast, By End Use, 2025 - 2032
       1. Hospital Pharmacy
       2. Retail Pharmacy
       3. Online Pharmacy
    8. Market Attractiveness Analysis
12. Competition Landscape
    1. Market Share Analysis, 2025
    2. Market Structure
       1. Competition Intensity Mapping By Market
       2. Competition Dashboard
    3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
       1. Biogen
          1. Overview
          2. Segments and Drug Class
          3. Key Financials
          4. Market Developments
          5. Market Strategy
       2. Pfizer, Inc.
       3. Hoffmann-La Roche Ltd.
       4. Merck & Co., Inc.
       5. Novartis AG
       6. Sanofi
       7. Teva Pharmaceutical Industries Ltd.
       8. Orion Pharma
       9. UCB S.A
       10. ACADIA Pharmaceuticals Inc.
       11. Lundbeck A/S
       12. Mitsubishi Tanabe Pharma Corporation
       13. Others
13. Appendix
    1. Research Methodology
    2. Research Assumptions
    3. Acronyms and Abbreviations